January 25, 2017
(Managed Care Magazine) – Real-world evidence (RWE) is the hot topic this year, a way to evaluate treatments—and make changes on the fly, if necessary—under a new president who thinks the FDA moves too slowly. Put simply, RWE looks at how well new medications and medical devices do after they’ve hit the market, relying on data collected outside of traditional clinical studies. Many drugs often don’t do well, said Shalilja Dixit, one of the presenters at a recent conference in Philadelphia by EyeforPharma, a worldwide company that seeks to keep the pharmaceutical industry relevant by tracking shifting trends. Dixit, who studies health outcomes for Intercept Pharmaceuticals, said that 49% of drugs do not have the same impact on outcomes that they had in clinical trials.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.